RNA Analytical/Quality Videos

  1. How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic 1/31/2023

    Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.

  2. What The EMA Guidance Means For mRNA: Progress, Limitations, And Future Directions 6/24/2025

    Advancing RNA panelists Tiffany Lucas and Ulrike Jägle home in on the EMA’s guidance for mRNA vaccine quality, sharing their initial thoughts on the guidance’s strengths, while also addressing its limitations for those of us who may be working with mRNA in a therapeutic context.

  3. The "Golden Idea Of The Platform" & Its Role In mRNA PD 8/22/2024

    Explore how early-stage companies can implement design space and analytical principles that will help us determine the biggest differences between constructs and how close we may be to a true “platform process.”

  4. Engaging Early In Process Development To Bring mRNA Sequences To Life

    Examine why template sequence characteristics are relevant for cGMP manufacturing of high-quality mRNA and consider insights on how to develop a scalable, robust, and economically viable process.

  5. What's In The Vial?! A [Brief] Meditation On Control Strategy

    Speakers in The State Of The mRNA Supply Chain event tackle an audience member’s question around what matters most: What’s in the vial or what’s in the process?

  6. The Purification Dilemma: Balancing Upstream & Downstream Investment 10/15/2025

    This Advancing RNA Live clip dives into the biggest challenges in mRNA purification and the critical debate on where to focus investment. Here, our three mRNA PD experts argue for a holistic process development strategy, challenging the traditional wisdom of optimizing the upstream process at any cost.

  7. Outgrowing Legacy Methods: mRNA's Transition from Protein Paradigms 6/9/2026

    AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov highlight the technical limitations of legacy analytical methods in evaluating and measuring mRNA-LNP concentration, structure, purity, integrity, and impurities.

  8. Polymerase Selection And Its Impact On IVT Outcomes For Self-Amplifying RNA 6/10/2026

    Polymerase selection has measurable consequences for IVT outcomes in saRNA production, affecting dsRNA byproduct levels, capping efficiency, total yield, and transcript integrity across long templates.

  9. How Should We Better Interrogate gRNA Design Today? 4/29/2026

    Advancing RNA Live speaker April Sena emphasizes the need for a collaborative, public safety dataset for chemical modifications to streamline regulatory approvals, while Max De Long points out a potential drug clearance conundrum as we continue to improve our gRNA’s durability and stability. 

  10. Strategies To De-Risk Next-Gen mRNA Raw Materials 12/3/2025

    In this Advancing RNA Live clip, Khaled Yamout and Sanofi’s Francoise Ribes share the quality considerations that are top of mind when evaluating a novel raw material, as well as how the broader industry (i.e., standard setting organizations, suppliers, and biotechs) can arrive at a clearer understanding of a material’s quality.